To participate in the cooperative approach to the design and conduct of clinical trials in malignant diseases. These diseases include leukemia, lymphoma, childhood solid tumors and other neoplasms to be studied by the Pediatric Oncology Group. These studies will be classified as Phase I for the evaluation of toxicity, tolerated dosage and therapeutic range of new combinations of agents; Phase II-to establish the relative efficacy of various therapeutic regiments in neoplastic diseases. Phase I studies will include clinical and experimental pharmacologic investigations such as absorption, plasma halftime, body fluid levels and excretion in man and animal models. To investigate some of the biochemical and biological aspects of the neoplasms under study as they derive from patient material available for the cooperative studies. To actively participate in and contribute to the overall Group effort. This will include scientific input, support in protocol design, chairmanship of studies and other activities called for. To contribute to the overall science of the group, do pilot studies and basic research studies through multidiscipline approach in our own institution and subsequently propose them for group wide use.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA028841-14
Application #
2087799
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1981-01-01
Project End
1995-12-31
Budget Start
1994-01-01
Budget End
1994-12-31
Support Year
14
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Kansas
Department
Pediatrics
Type
Schools of Medicine
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160